Drug Trial Radar · NCT07608757
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Feb 2027
Primary completion
Feb 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- Caliway Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A phase 2b, randomized, placebo-controlled study with long-term re-treatment to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
Conditions
- Subcutaneous Fat
Interventions
CBL-514 InjectionDrug
Provided as a ready for use injectable CBL-514 solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change of abdominal fatTime frame: From baseline to 4 weeks after final treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigational Site 1
South Yarra, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.